Moreover, a recent meta-analysis has investigated, in head-to-head comparison, the role of endocrine treatment versus chemotherapy in postmenopausal setting with HR+ and HER2− metastatic disease, highlighting that bevacizumab in combination with paclitaxel was the only regimen that was significantly better than palbociclib plus letrozole in terms of response rate22. The gene discussed is HR; the disease is metastatic neoplasm.